版本:
中国

BRIEF-Madrigal Pharmaceuticals Q4 loss per share $0.67

April 3 Madrigal Pharmaceuticals Inc

* Madrigal Pharmaceuticals reports 2016 fourth quarter and year-end financial results, reviews key corporate achievements and provides update on lead clinical-stage compound, MGL-3196

* Qtrly loss per share $0.67 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐